Holen Sie sich die Stockscreener-App
14.00
5.53%
-0.82
Handel nachbörslich:
13.89
-0.11
-0.79%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt TNDM?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$14.82
Offen:
$14.81
24-Stunden-Volumen:
1.75M
Relative Volume:
0.84
Marktkapitalisierung:
$945.97M
Einnahmen:
$796.00M
Nettoeinkommen (Verlust:
$-136.49M
KGV:
-6.6986
EPS:
-2.09
Netto-Cashflow:
$-64.24M
1W Leistung:
-4.83%
1M Leistung:
+13.18%
6M Leistung:
-17.84%
1J Leistung:
-61.26%
1-Tages-Spanne:
$13.49
$14.81
1-Wochen-Bereich:
$13.49
$15.57
52-Wochen-Spanne:
$9.98
$38.94
Tandem Diabetes Care Inc Stock (TNDM) Company Profile
Firmenname
Tandem Diabetes Care Inc
Sektor
Branche
Telefon
858-366-6900
Adresse
12400 HIGH BLUFF DRIVE, San Diego, CA
Vergleichen Sie TNDM mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TNDM
Tandem Diabetes Care Inc
|
14.00 | 1.00B | 796.00M | -136.49M | -64.24M | -2.09 |
|
ABT
Abbott Laboratories
|
132.57 | 232.02B | 43.11B | 13.94B | 6.78B | 7.9963 |
|
BSX
Boston Scientific Corp
|
95.41 | 144.14B | 18.49B | 2.50B | 3.49B | 1.6801 |
|
SYK
Stryker Corp
|
364.60 | 141.53B | 23.82B | 2.92B | 4.02B | 7.5574 |
|
MDT
Medtronic Plc
|
95.45 | 123.78B | 34.20B | 4.69B | 5.30B | 3.6218 |
|
EW
Edwards Lifesciences Corp
|
73.94 | 44.14B | 5.69B | 1.41B | 577.90M | 6.9828 |
Tandem Diabetes Care Inc Stock (TNDM) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-09-08 | Eingeleitet | Oppenheimer | Outperform |
| 2025-08-12 | Hochstufung | Citigroup | Sell → Neutral |
| 2025-08-07 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2025-07-09 | Herabstufung | Citigroup | Neutral → Sell |
| 2025-06-16 | Eingeleitet | Truist | Hold |
| 2025-04-10 | Eingeleitet | Mizuho | Neutral |
| 2025-03-05 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2025-03-04 | Herabstufung | Citigroup | Buy → Neutral |
| 2025-03-03 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2025-02-28 | Herabstufung | Bernstein | Outperform → Mkt Perform |
| 2024-12-02 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2024-11-06 | Eingeleitet | Bernstein | Outperform |
| 2024-10-04 | Eingeleitet | Goldman | Neutral |
| 2024-10-02 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2024-08-22 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2024-08-08 | Eingeleitet | Canaccord Genuity | Buy |
| 2024-05-30 | Eingeleitet | Redburn Atlantic | Buy |
| 2024-05-22 | Hochstufung | Citigroup | Neutral → Buy |
| 2024-04-29 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2024-04-25 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2024-03-26 | Hochstufung | Stifel | Hold → Buy |
| 2023-08-04 | Herabstufung | Citigroup | Buy → Neutral |
| 2023-05-05 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2023-04-24 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2023-03-29 | Eingeleitet | UBS | Neutral |
| 2023-01-26 | Eingeleitet | Wolfe Research | Peer Perform |
| 2022-11-15 | Hochstufung | Wells Fargo | Underweight → Equal Weight |
| 2022-10-18 | Eingeleitet | Barclays | Overweight |
| 2022-10-12 | Eingeleitet | Jefferies | Buy |
| 2022-08-09 | Herabstufung | Wells Fargo | Overweight → Underweight |
| 2022-03-02 | Fortgesetzt | BofA Securities | Neutral |
| 2022-01-19 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2021-07-21 | Fortgesetzt | Cowen | Outperform |
| 2021-05-25 | Eingeleitet | Barclays | Underweight |
| 2020-12-15 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2020-08-20 | Eingeleitet | Wells Fargo | Overweight |
| 2020-07-31 | Hochstufung | Guggenheim | Neutral → Buy |
| 2020-07-06 | Hochstufung | Citigroup | Neutral → Buy |
| 2020-06-18 | Bestätigt | Raymond James | Outperform |
| 2020-04-24 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2020-03-23 | Herabstufung | Guggenheim | Buy → Neutral |
| 2020-03-05 | Eingeleitet | Citigroup | Neutral |
| 2020-02-06 | Eingeleitet | Raymond James | Outperform |
| 2020-02-04 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2019-10-18 | Eingeleitet | Guggenheim | Buy |
| 2019-10-04 | Hochstufung | UBS | Neutral → Buy |
| 2019-05-17 | Bestätigt | BofA/Merrill | Neutral |
| 2019-05-13 | Eingeleitet | SVB Leerink | Outperform |
| 2019-03-08 | Eingeleitet | BMO Capital Markets | Outperform |
| 2019-03-05 | Bestätigt | BofA/Merrill | Neutral |
| 2019-02-27 | Bestätigt | Lake Street | Buy |
| 2018-11-21 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2018-09-26 | Bestätigt | Dougherty & Company | Buy |
| 2018-09-26 | Bestätigt | Piper Jaffray | Overweight |
Alle ansehen
Tandem Diabetes Care Inc Aktie (TNDM) Neueste Nachrichten
United States Wearable Injectors Market 2025 | Industry - openPR.com
Tandem Diabetes Care Inc. stock momentum explainedPortfolio Profit Report & Community Supported Trade Ideas - newser.com
Can Tandem Diabetes Care Inc. stock deliver sustainable ROEJuly 2025 Institutional & Growth Focused Entry Reports - newser.com
Is Tandem Diabetes Care Inc. stock attractive after correction2025 Price Action Summary & Reliable Entry Point Trade Alerts - newser.com
Lobbying Update: $50,000 of TANDEM DIABETES CARE lobbying was just disclosed - Quiver Quantitative
TNDM Investor News: If You Have Suffered Losses in Tandem Diabetes Care, Inc. (NASDAQ: TNDM), You Are Encouraged to Contact The Rosen Law Firm About Your Rights - GlobeNewswire Inc.
Is this a good reentry point in Tandem Diabetes Care Inc.Portfolio Growth Summary & Weekly Sector Rotation Insights - newser.com
Is Tandem Diabetes Care Inc. (TD5A) stock undervalued after correctionTrade Risk Summary & Community Trade Idea Sharing - newser.com
Should you hold or exit Tandem Diabetes Care Inc. nowJuly 2025 Short Interest & Breakout Confirmation Trade Signals - newser.com
Ongoing Securities Investigation into Tandem Diabetes Care, Inc. (TNDM)Contact Levi & Korsinsky - Newsfile
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Tandem Diabetes Care, Inc.TNDM - PR Newswire
Tandem Diabetes Care Stock Soars 12.2% to Intraday High of $14.85 - Markets Mojo
Tandem Diabetes Care Experiences Revision in Stock Evaluation Amid Market Fluctuations - Markets Mojo
INVESTOR ALERT: Investigation of Tandem Diabetes Care, Inc. (TNDM) Announced by Holzer & Holzer, LLC - GlobeNewswire
TNDM: Citigroup Raises Price Target to $15, Maintains Neutral Ra - GuruFocus
Shareholders Alert: Investigation Into Tandem Diabetes Care, Inc. (TNDM)Contact Levi & Korsinsky to Protect Your Rights - ACCESS Newswire
Why Analysts Are Reassessing Tandem Diabetes Care as Its Growth Story Evolves - Yahoo Finance
Is Tandem Diabetes Care Inc. (TD5A) stock a contrarian opportunityPortfolio Value Summary & Daily Volume Surge Signals - newser.com
Is Tandem Diabetes Care Inc. (TD5A) stock a top pick for value investorsJuly 2025 EndofMonth & High Accuracy Swing Entry Alerts - newser.com
Fraud Investigation Opened: Levi & Korsinsky Investigates Tandem Diabetes Care, Inc. (TNDM) on Behalf of Shareholders - ACCESS Newswire
Published on: 2025-10-06 08:09:28 - earlytimes.in
Investors in Tandem Diabetes Care, Inc. (TNDM) Warned of Potential Securities FraudContact Levi & Korsinsky Today - ACCESS Newswire
Forecasting Tandem Diabetes Care Inc. price range with options dataEarnings Trend Report & Precise Swing Trade Entry Alerts - newser.com
Will Tandem Diabetes Care Inc. (TD5A) stock keep raising dividendsWeekly Profit Analysis & Fast Entry Momentum Alerts - newser.com
Published on: 2025-10-05 04:46:17 - newser.com
Applying big data sentiment scoring on Tandem Diabetes Care Inc.Quarterly Market Review & Fast Gain Stock Trading Tips - newser.com
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Tandem Diabetes Care, Inc.TNDM - MarketScreener
Does Tandem Diabetes Care Inc. fit your quant trading modelJuly 2025 Pullbacks & Weekly Top Gainers Alerts - newser.com
Will Tandem Diabetes Care Inc. stock go up soonQuarterly Profit Review & Smart Allocation Stock Tips - newser.com
Published on: 2025-10-03 00:29:08 - newser.com
Why Tandem Diabetes Care Inc. stock remains a top recommendation - newser.com
Lost Money on Tandem Diabetes Care, Inc. (TNDM)? Contact Levi & Korsinsky to Protect Your Rights - ACCESS Newswire
Press Release: Tandem Diabetes Care to Announce Third Quarter 2025 Financial Results on November 6, 2025 - 富途牛牛
ContactThe Lethbridge HeraldNews and Sports from around Lethbridge - FinancialContent
agilon health, Tandem Diabetes, NeoGenomics, Hims & Hers Health, and Oscar Health Stocks Trade Up, What You Need To Know - The Globe and Mail
FDA clearances: Karl Storz, Tandem Diabetes Care, AngioSafe - Modern Healthcare
Tandem Diabetes Care to Announce Third Quarter 2025 Financial Results on November 6, 2025 - 富途牛牛
ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Tandem Diabetes Care, Inc. Investors to Inquire About Securities Class Action Investigation - AllSides
Securities Fraud Investigation Into Tandem Diabetes Care, - GlobeNewswire
TNDM Investor News: If You Have Suffered Losses in Tandem - GlobeNewswire
Finanzdaten der Tandem Diabetes Care Inc-Aktie (TNDM)
Umsatz
Nettogewinn
Free Cashflow
ENV
Tandem Diabetes Care Inc-Aktie (TNDM) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Novara Mark David | EVP & CHIEF COMMERCIAL OFFICER |
Sep 15 '25 |
Option Exercise |
0.00 |
7,415 |
0 |
36,214 |
| Novara Mark David | EVP & CHIEF COMMERCIAL OFFICER |
Aug 15 '25 |
Option Exercise |
0.00 |
76 |
0 |
28,839 |
| Morrison Susan | EVP & Chief Admin. Officer |
Aug 15 '25 |
Option Exercise |
0.00 |
2,600 |
0 |
39,376 |
| Sheridan John F | PRESIDENT & CEO |
Aug 15 '25 |
Option Exercise |
0.00 |
11,453 |
0 |
115,001 |
| Carpenter Rick | Chief Technology Officer |
Aug 15 '25 |
Option Exercise |
0.00 |
2,335 |
0 |
22,824 |
| Vosseller Leigh | EVP & CHIEF FINANCIAL OFFICER |
Aug 15 '25 |
Option Exercise |
0.00 |
2,998 |
0 |
36,258 |
| Hansen Shannon Marie | EVP & Chief Legal Officer |
Aug 15 '25 |
Option Exercise |
0.00 |
3,065 |
0 |
19,102 |
| Gasser Elizabeth Anne | EVP, Chief Strategy Officer |
Aug 15 '25 |
Option Exercise |
0.00 |
2,600 |
0 |
1,795 |
| Sheridan John F | PRESIDENT & CEO |
Aug 11 '25 |
Buy |
10.23 |
10,000 |
102,318 |
106,327 |
| Vosseller Leigh | EVP & CHIEF FINANCIAL OFFICER |
Aug 08 '25 |
Buy |
10.89 |
13,720 |
149,404 |
25,580 |
1.83%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):